149 related articles for article (PubMed ID: 10971207)
1. Pharmacogenetics of the human arylamine N-acetyltransferases.
Grant DM; Goodfellow GH; Sugamori K; Durette K
Pharmacology; 2000 Sep; 61(3):204-11. PubMed ID: 10971207
[TBL] [Abstract][Full Text] [Related]
2. Human acetyltransferase polymorphisms.
Grant DM; Hughes NC; Janezic SA; Goodfellow GH; Chen HJ; Gaedigk A; Yu VL; Grewal R
Mutat Res; 1997 May; 376(1-2):61-70. PubMed ID: 9202739
[TBL] [Abstract][Full Text] [Related]
3. Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes.
Grant DM; Blum M; Beer M; Meyer UA
Mol Pharmacol; 1991 Feb; 39(2):184-91. PubMed ID: 1996083
[TBL] [Abstract][Full Text] [Related]
4. Arylamine N-acetyltransferases: structural and functional implications of polymorphisms.
Sim E; Lack N; Wang CJ; Long H; Westwood I; Fullam E; Kawamura A
Toxicology; 2008 Dec; 254(3):170-83. PubMed ID: 18852012
[TBL] [Abstract][Full Text] [Related]
5. Differences between murine arylamine N-acetyltransferase type 1 and human arylamine N-acetyltransferase type 2 defined by substrate specificity and inhibitor binding.
Laurieri N; Kawamura A; Westwood IM; Varney A; Morris E; Russell AJ; Stanley LA; Sim E
BMC Pharmacol Toxicol; 2014 Nov; 15():68. PubMed ID: 25432241
[TBL] [Abstract][Full Text] [Related]
6. Structure-function studies of human arylamine N-acetyltransferases NAT1 and NAT2. Functional analysis of recombinant NAT1/NAT2 chimeras expressed in Escherichia coli.
Dupret JM; Goodfellow GH; Janezic SA; Grant DM
J Biol Chem; 1994 Oct; 269(43):26830-5. PubMed ID: 7929420
[TBL] [Abstract][Full Text] [Related]
7. Metabolic activation of heterocyclic aromatic amines catalyzed by human arylamine N-acetyltransferase isozymes (NAT1 and NAT2) expressed in Salmonella typhimurium.
Wild D; Feser W; Michel S; Lord HL; Josephy PD
Carcinogenesis; 1995 Mar; 16(3):643-8. PubMed ID: 7697826
[TBL] [Abstract][Full Text] [Related]
8. Arylamine N-acetyltransferases: characterization of the substrate specificities and molecular interactions of environmental arylamines with human NAT1 and NAT2.
Liu L; Von Vett A; Zhang N; Walters KJ; Wagner CR; Hanna PE
Chem Res Toxicol; 2007 Sep; 20(9):1300-8. PubMed ID: 17672512
[TBL] [Abstract][Full Text] [Related]
9. Metabolic activation of N-hydroxy-2-aminofluorene and N-hydroxy-2-acetylaminofluorene by monomorphic N-acetyltransferase (NAT1) and polymorphic N-acetyltransferase (NAT2) in colon cytosols of Syrian hamsters congenic at the NAT2 locus.
Hein DW; Doll MA; Gray K; Rustan TD; Ferguson RJ
Cancer Res; 1993 Feb; 53(3):509-14. PubMed ID: 8425184
[TBL] [Abstract][Full Text] [Related]
10. Identification of single-nucleotide polymorphisms (SNPs) of human N-acetyltransferase genes NAT1, NAT2, AANAT, ARD1 and L1CAM in the Japanese population.
Sekine A; Saito S; Iida A; Mitsunobu Y; Higuchi S; Harigae S; Nakamura Y
J Hum Genet; 2001; 46(6):314-9. PubMed ID: 11393533
[TBL] [Abstract][Full Text] [Related]
11. Acetylator status, drug metabolism and disease.
Pande JN; Pande A; Singh SP
Natl Med J India; 2003; 16(1):24-6. PubMed ID: 12715953
[TBL] [Abstract][Full Text] [Related]
12. Arylamine N-acetyltransferases: from drug metabolism and pharmacogenetics to drug discovery.
Sim E; Abuhammad A; Ryan A
Br J Pharmacol; 2014 Jun; 171(11):2705-25. PubMed ID: 24467436
[TBL] [Abstract][Full Text] [Related]
13. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms.
Hein DW; Doll MA; Fretland AJ; Leff MA; Webb SJ; Xiao GH; Devanaboyina US; Nangju NA; Feng Y
Cancer Epidemiol Biomarkers Prev; 2000 Jan; 9(1):29-42. PubMed ID: 10667461
[TBL] [Abstract][Full Text] [Related]
14. [N-acetyltransferase genetic polymorphism and its role in the development of neoplastic disease].
Lutz W
Med Pr; 2000; 51(3):277-84. PubMed ID: 11002474
[TBL] [Abstract][Full Text] [Related]
15. Isoform-selective inactivation of human arylamine N-acetyltransferases by reactive metabolites of carcinogenic arylamines.
Liu L; Wagner CR; Hanna PE
Chem Res Toxicol; 2009 Dec; 22(12):1962-74. PubMed ID: 19842618
[TBL] [Abstract][Full Text] [Related]
16. Generation and functional characterization of arylamine N-acetyltransferase Nat1/Nat2 double-knockout mice.
Sugamori KS; Wong S; Gaedigk A; Yu V; Abramovici H; Rozmahel R; Grant DM
Mol Pharmacol; 2003 Jul; 64(1):170-9. PubMed ID: 12815173
[TBL] [Abstract][Full Text] [Related]
17. Genetic polymorphism in N-Acetyltransferase (NAT): Population distribution of NAT1 and NAT2 activity.
Walker K; Ginsberg G; Hattis D; Johns DO; Guyton KZ; Sonawane B
J Toxicol Environ Health B Crit Rev; 2009; 12(5-6):440-72. PubMed ID: 20183529
[TBL] [Abstract][Full Text] [Related]
18. Polymorphic NATs and cancer predisposition.
Hirvonen A
IARC Sci Publ; 1999; (148):251-70. PubMed ID: 10493262
[TBL] [Abstract][Full Text] [Related]
19. Polymorphism p.Val231Ile alters substrate selectivity of drug-metabolizing arylamine N-acetyltransferase 2 (NAT2) isoenzyme of rhesus macaque and human.
Tsirka T; Boukouvala S; Agianian B; Fakis G
Gene; 2014 Feb; 536(1):65-73. PubMed ID: 24333853
[TBL] [Abstract][Full Text] [Related]
20. Metabolic activation of aromatic and heterocyclic N-hydroxyarylamines by wild-type and mutant recombinant human NAT1 and NAT2 acetyltransferases.
Hein DW; Rustan TD; Ferguson RJ; Doll MA; Gray K
Arch Toxicol; 1994; 68(2):129-33. PubMed ID: 8179482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]